This trial is testing a new drug to see if it's effective and safe for people with cancer who have a specific mutation.
- Gorlin Syndrome
1 Primary · 9 Secondary · Reporting Duration: through study completion, an average of 6 months
2 Treatment Groups
300 mg ENV-101
1 of 2
200 mg ENV-101
1 of 2
44 Total Participants · 2 Treatment Groups
Primary Treatment: ENV-101 (taladegib) · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are investigators currently enrolling participants in this research?
"Affirmative. According to the information hosted on clinicaltrials.gov, this experiment is actively searching for potential participants and was initially posted on May 24th 2022. 44 individuals need to be enrolled from 18 different medical locations with November 28th being its most recent update." - Anonymous Online Contributor
What has been the Food and Drug Administration's stance on taladegib (ENV-101) thus far?
"Taladegib (ENV-101) has been assigned a safety rating of 2, as this Phase 2 trial has yielded some data on its security but not yet any proof of efficacy." - Anonymous Online Contributor
How many medical sites are administering this clinical trial?
"This medical experiment is presently enrolling patients from 18 different sites across the US, including Tampa, Madison and San Diego. To reduce difficulties associated with travel, it's suggested that participants select a clinic nearest to them." - Anonymous Online Contributor
How many individuals are being monitored as part of this scientific investigation?
"Affirmative. Clinicaltrials.gov documents show that since its announcement on May 24th 2022, this research study has been actively recruiting participants at 18 different sites and is still searching for 44 more volunteers to join the trial." - Anonymous Online Contributor